Takeda Announces ThirdQuarter FY2023 Results OnTrack Towards

Takeda TOKYO4502NYSETAK today announced financial results for the third quarter of fiscal year 2023 period ended December 31 2023. With yeartodate strong momentum in its Growth Launch Products 12.7 at CER offsetting the significant revenue impact of generic entrants Takeda remains on track towards its fullyear Management Guidance.

Related Keywords

China , United States , Osaka , Japan , Christopher Oreilly , Takeda Pharmaceutical Company Limited , Actual Exchange Rate , Digital Technology , Constant Exchange Rate , International Financial Reporting Standards , Exchange Commission , Ultra Rare Blood Clotting Disorder , Commercial Execution Maximizing Value , Existing Portfolio , Pen Launched , Ulcerative Colitis , Disease Filing Expected , Dengue Vaccine Now Launched , Refractory Post Transplant , Operating Profit Change , Reflecting Generic Impact , Lower Coronavirus Vaccines Revenue , Increased Investment , Cycle Management Approvals , January Support Forward Momentum , Launch Products , Costa Saroukos , Management Guidance , Free Cash Flow , Annual Report , Score Revenue , Core Operating Profit , Core Net Profit , Net Debt , Free Cash , Media Contact , Takeda Pharmaceutical Company Limited Takedas Fy2023 Q3 Results Forecast Costa Saroukos Tak279 Nimbus Fruzaqla Hutchmed Earnings Thirdquarter Growth Launch Products Management Guidance Cer Fourth Quarter Financial Treatments Plasmaderived Therapies Health Oncology Neuroscience Rd Vaccines Biopharmaceutical ,